In Brief
Refine Search
Pharmaceutical
UK-based immunotherapy firm Centauri Therapeutics has secured a £1 million ($1.25 million) grant from PACE (Pathways to Antimicrobial Clinical Efficacy) to further develop its Alphamer technology. 25 November 2024
Biotechnology
Germany’s Evotec says it has taken notice of the statement made by Halozyme Therapeutics on November 22, stating that it has withdrawn its non-binding proposal to acquire Evotec for 11.00 euros per share in cash. 23 November 2024
Biotechnology
Colorado, USA-based OncoVerity announced the closing of a series A extension led by existing investors, argenX and RefinedScience. The value was not disclosed, but this extension follows a $30 million Series A fundraiser in March 2023. 22 November 2024
Biotechnology
Sweden-based BioArctic saw its fall 7.5% to 139.90 kronor on Friday, after its announced that its partner, Japan’s Eisa, has updated its revenue outlook for the Alzheimer’s treatment Leqembi (lecanemab) for the 2024 fiscal year (FY), which runs from April 2024 through March 2025. 11 November 2024
Biotechnology
Danish biotech Gubra announces that Germany’s Boehringer Ingelheim has decided to discontinue the development of the long-acting neuropeptide Y receptor type 2 (NPY2R) agonist BI 1820237 in obesity. 4 November 2024
Biotechnology
Japanese drugmaker Eisai has completed the rolling submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for lecanemab-irmb (US brand name Leqembi) subcutaneous autoinjector for weekly maintenance dosing after it was granted Fast Track designation by the FDA. 1 November 2024
Pharmaceutical
GSK has announced its largest US manufacturing investment to date, dedicated to producing medicines and vaccines. 25 October 2024
Pharmaceutical
Following a re-examination, the European Medicines Agency’s human health committee, CHMP confirmed its initial recommendation to refuse the granting of a conditional marketing authorization for Masitinib AB Science’s masitinib. 18 October 2024
Pharmaceutical
University Medical Center Groningen (UMCG) and SHINE Europe have secured a 10.5 million euro ($11 million) grant to advance European production of terbium isotopes for cancer treatments. 17 October 2024
Pharmaceutical
Danish dermatology focused LEO Pharma has announced the launch of Anzupgo (delgocitinib) cream in Germany for the treatment of adult patients with moderate to severe chronic hand eczema (CHE), for whom topical corticosteroids are inadequate or inappropriate. 15 October 2024
Pharmaceutical
French pharma major Sanofi revealed it has entered into negotiations with private equity firm Clayton Dubilier & Rice (CD&R) for the potential sale of a 50% controlling stake in Opella, its consumer healthcare business. 14 October 2024
Pharmaceutical
The UK’s new 2024 voluntary scheme for branded medicines pricing, access, and growth (VPAG) came into force at the beginning of January this year. 4 October 2024
Biotechnology
Sirnaomics, a firm specializing in RNAi therapeutics, has entered into a subscription agreement with biotech specialist Poon Hung Fai. 4 October 2024
Biotechnology
GigaGen has been awarded a contract by the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the US Department of Health and Human Services (HHS). 4 October 2024
Biotechnology
Oxford, UK-based Enara Bio today announces the closing of a $32.5 million Series B financing supported by a strong syndicate of new and existing biotech investors. 3 October 2024
Pharmaceutical
French drugmaker Mitem Pharmavhas the worldwide acquisition of Desferal (deferoxamine), a major MITM in hematology, from Swiss giant Novartis. 25 September 2024
article
The European Medicines Agency’s (EMA) Committee for Human Medicinal Products (CHMP) has elected Bruno Sepodes as its new chair. 19 September 2024
Pharmaceutical
The Austrian Academy of Sciences (OeAW) is further expanding its focus on life sciences by opening an institute for biomedical artificial intelligence (AI) based on a 150 million euros ($166.8 million) funding from the German non-profit Boehringer Ingelheim Foundation (BIS). 18 September 2024
Biotechnology
Zenas BioPharma announced the pricing of its upsized initial public offering of 13,235,294 shares of its common stock at an initial public offering price of $17.00 per share. 13 September 2024
Biotechnology
French venture capital firm Sofinnova Partners has announced the closing of a $200 million fund, spearheaded by partners Edward Kliphuis and Simon Turner. 27 October 2023
Pharmaceutical
US pharma major AbbVie’s shares were down 3.3% at $140.24 early today, after it released financial results for the third quarter of 2023. 27 October 2023
Biotechnology
Swiss pharma giant Roche has announced that the US Food and Drug Administration (FDA) has approved Vabysmo (faricimab) for the treatment of macular edema following retinal vein occlusion (RVO). 27 October 2023
Biotechnology
The UK’s National Institute for Health and Care Excellence (NICE) has issued final draft guidance, recommending the use of Cosentyx (secukinumab) as a treatment option for adults in England and Wales with active moderate to severe hidradenitis suppurativa (HS). 27 October 2023
Pharmaceutical
Tokyo-headquartered pharma major Takeda has announced results for the first half of its fiscal year, which in Japan runs from April 1 to September 1. 27 October 2023
Pharmaceutical
Japanese drugmaker Otsuka today announced positive results of two, six-week, Phase III clinical trials that evaluated the efficacy, safety, and tolerability of centanafadine for the treatment of adolescents and children with attention-deficit/hyperactivity disorder (ADHD). 27 October 2023
Pharmaceutical
The US Food and Drug Administration (FDA) yesterday approved the new drug application (NDA) for Agamree (vamorolone) as a treatment of patients aged two years or more with Duchenne muscular dystrophy (DMD), that was submitted by Swiss drugmaker Santhera Pharmaceuticals. 27 October 2023
Biosimilars
Sandoz, the generic and biosimilar medicines business of Swiss pharma giant Novartis that was fully spun out on October 4, announced the issuance of two highly successful inaugural CHF bonds with gross proceeds of 750 million francs ($843 million). 27 October 2023
Pharmaceutical
Pharma giant Merck & Co was trading more than 2% higher Thursday lunchtime, as the firm released financial results. 26 October 2023
Biosimilars
The European Union is currently reviewing its pharmaceutical legislation, and the latest IQVIA white paper “Assessing the biosimilar void” sheds light on the growing biological medicines market and the opportunity to improve equitable access with biosimilar medicines competition. 26 October 2023
Biotechnology
Gene editing company Verve Therapeutics has been cleared by the US regulator to go ahead with what will be the first in-human base editing study in the country, 26 October 2023
Biotechnology
Eisai and Biogen have announced the presentation of new data for their Alzheimer’s drug Leqembi (lecanemab-irmb) 100mg/mL injection for intravenous (IV) use. 26 October 2023
Pharmaceutical
US pharma giant Merck & Co has opted to pull the plug on two mid-stage trials of Alzheimer’s disease candidate MK-1942, due to safety worries. 26 October 2023
Pharmaceutical
US Pharma major Bristol Myers Squibb today reported results for the third quarter of 2023, which the company says reflect significant pipeline progress and advances in the portfolio renewal strategy. 26 October 2023
Biotechnology
Privately-held Italian drugmaker Dompé has announced the appointment of Shannon Sullivan as is chief commercial officer (CCO), with immediate effect. 26 October 2023
Biotechnology
Independent data monitors have recommended that French microbiome specialist MaaT Pharma continues its Phase III ARES study without modification. 26 October 2023
Pharmaceutical
Danish diabetes care giant Novo Nordisk recently revealed that its FLOW trial, which studies Ozempic (semaglutide) in diabetic patients with chronic kidney disease (CKD), will come to a halt almost one year prior to the planned completion date, as interim results alone were sufficient in proving that the treatment was successful in treating kidney failure in this patient group. 26 October 2023
Pharmaceutical
China’s National Medical Products Administration (NMPA) has approved ViiV Healthcare’s Vocabria (cabotegravir injection) used in combination with Rekambys (rilpivirine long-acting injection) for the treatment of HIV-1 infection. 26 October 2023
Pharmaceutical
USA-based BioXcel Therapeutics on Wednesday revealed that an independent third-party review of the data from a site in its TRANQUILITY II Phase III trial showed "positive findings." 26 October 2023
Biotechnology
UK-based Revolo Biotherapeutics, which is developing therapies that reset the immune system to achieve superior long-term remission for patients with autoimmune and allergic diseases, has announced top-line data from its allergen challenge mapping study. 25 October 2023
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze